A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

Trial Profile

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms DOVE-M
  • Most Recent Events

    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
    • 21 May 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 15 Aug 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top